SYNOPSIS Nomifensine, a tetrahydroisoquinoline antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those induced by levodopa.
Nomifensine (8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline) is a drug currently being evaluated as an antidepressant. It inhibits the reuptake of noradrenaline in the same way as tricyclic antidepressants, but unlike tricyclics it also decreases the reuptake of dopamine and has a direct agonist effect on dopaminergic receptors (Hoffmann, 1973; Gerhards et al., 1974; Schacht and Heptner, 1974; . Nomifensine should therefore potentiate both noradrenergic and dopaminergic synaptic transmission. There is evidence, deriving from animal studies, which suggests that optimal anti-Parkinsonism therapy should augment both noradrenergic and dopaminergic transmission (Hornykiewicz, 1973) The major adverse effect was dyskinesia. In four patients this was controlled by a reduction in levodopa from a mean of 3.63 g (range 4.5 to 3) to a mean of2.5 g (range 3.5 to 1.5) and in two subjects by a reduction of Sinemet (250 mg levodopa combined with 25 mg carbidopa) from an average of 3.75 tablets (range 5 to 2.5) to an average of two (range 3 to 1). Other concomitant therapy was maintained without alteration throughout the study.
EVALUATIONS
The method for evaluation of physical signs and functional disability was that used previously (Calne et al., 1974) , scores ranging from 0 (representing normality) to 4 (maximum deficit). Timed The results of the last three evaluations on nomifensine were compared with the three evaluations on placebo. When placebo was substituted for active drug, deterioration of physical signs and functional disability were significant ( Fig. 1) at the 0.1 % level (paired t test). Of the physical signs, tremor and facial expression improved most during treatment with nomifensine, but there was also some amelioration of rigidity, speech disorder, balance, finger dexterity, gait, posture, and drooling of saliva. Of the functional disabilities, dressing, washing, eating, and writing all improved. All timed tests showed a beneficial trend during treatment with nomifensine, for finger flexion (Fig. 2) the improvement was significant at the 1 % level (paired t test).
No statistical difference was found in either clinical scoring or timed tests between the patients receiving nomifensine for six, eight, 10, 12, 14 or 15 weeks.
Although all clinical features which were evaluated displayed some improvement during the phase of nomifensine therapy, gains were moderate and dramatic individual improvements were not seen.
The frequency of unwanted effects, in the 19 patients who completed the study, is shown in the Table. All adverse reactions were dose dependent and the drug was well tolerated once optimum maintenance levels of intake were established.
Of the nine patients omitted from the analysis, one failed to attend regularly and another had a continuing depressive illness, resistant to nomifensine. The other seven patients were withdrawn because of the development of involuntary movements; three of these were not receiving levodopa. Additional adverse effects in the excluded group included insomnia (two), confusion (two) and akathisia, headache, vertigo, faintness, emesis or constipation (one patient each). Some patients experienced more than one unwanted effect, but all the adverse reactions were abolished by stopping nomifensine. Our results suggest that nomifensine is effective in the treatment of Parkinsonism.
The frequency of adverse effects is similar to those produced by levodopa and bromocriptine. The prevalence of involuntary movements suggests that the pharmacological effect of nomifensine is similar to these agents, though many of the patients were concomitantly receiving levodopa. It is therefore difficult to evaluate the contribution of nomifensine to these reactions.
The M1-metabolite of nomifensine has similar activity to its parent compound in animal studies 
